Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 46 of 78 for:    DIPG

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (HGG-CilMetro)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01517776
Recruitment Status : Terminated (due to an altered benefit/risk assessment.)
First Posted : January 25, 2012
Last Update Posted : July 21, 2015
Sponsor:
Collaborator:
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
Christof Kramm, Martin-Luther-Universität Halle-Wittenberg

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : March 2014
Actual Study Completion Date : April 2014
Certification/Extension First Submitted : May 26, 2015